Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), a developer of RNA interference (RNAi) therapeutics, provided an update on its Ebola program late Tuesday night. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) said it commenced limited GMP manufacture of a new therapeutic specifically targeting the Ebola - Guinea variant, which is the viral variant responsible for the Ebola epidemic currently prevalent in West Africa. Supply of the new product will be available in early December, 2014, for potential use by various collaborators. As definitive agreements are established it said it will provide updates accordingly.The genomic sequence of the Ebola virus responsible for the current outbreak in West Africa has been determined from several viral isolates. The company has completed the design of a modified RNAi therapeutic specifically targeting this viral variant, now termed 'Ebola-Guinea.' The ability to rapidly and accurately match the evolving genetic sequences of emerging infectious agents is one of the powerful features of RNAi therapeutics. The company's IND for TKM-Ebola remains on partial clinical hold with respect to the multiple ascending dosing in healthy subjects. The company said it expect the matter to be resolved this quarter.Clean Energy Fuels Corp (NASDAQ:CLNE) Wednesday said it plans a natural-gas station to fuel LNG trucks for Giant/Martin's, grocery retailer, in Carlisle, Penn. The CLNE outlet will operate at the existing Flying J station. Clean Energy Fuels Corp (NASDAQ:CLNE), which sells compressed and liquified natural gas to trucks, buses and other vehicles, also reported that 43 new fleet customers began fueling at CLNE's national network of stations in Q3. CLNE did not provide a comparable figure for 2103. Among the new customers were refuse truck operators in Salt Lake County, UT, and Islip, NY.Stanley Black & Decker, Inc. (NYSE:SWK), a provider of tools, security, healthcare and engineering products, announced Q3 results that topped the Street view on both EPS and total revenues. The company reported Q3 EPS of $1.55, up from $1.39 in Q3 2013 and beating analyst estimates of $1.44 for the quarter. Total revenues of $2.90 billion were up from $2.75 billion in Q3 2013 and surpassed analyst projections of $2.87 billion."We are reiterating the mid-point while tightening our previously communicated 2014 EPS outlook range to $5.52 - $5.58 on an adjusted basis or $5.40 - $5.46 on a GAAP basis," said Donald Allan Jr., Senior Vice President and CFO, commented. "The mid-point of our full year EPS outlook remains unchanged as we expect the stronger than expected operational performance including our continued focus on indirect cost control and price management to offset the unfavorable impact of the current challenging macro environment, which is causing further currency pressure. We now estimate the full year currency impact to be approximately $75 million, up from our prior estimate of $60 million." The Street view for non-GAAP full year earnings is $5.53 per share, according to Capital IQ.Stanley Black & Decker, Inc. (NYSE:SWK) also raised its 2014 free cash flow estimate to approximately $800 million from prior estimate of at least $675 million based on lower one-time restructuring payments, working capital performance, and slightly lower levels of capital expenditures. SWK is considering cost reduction actions that could require additional restructuring charges of $10 - $25 million in excess of its current 2014 estimate of $25 million. The company expects its business strategy to improve cash flow return on investment by approximately 250 basis points through 2015.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
